Juyuan Research raises target for Innovent stock to HKD 138.63

Published on 10/17/2026 at 19:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

ESMO data are due October 23, 2026. Innovent stock stood at HKD 89.05 on October 16, 2026, up 1.48 percent in Hong Kong.

Analyst view and valuation

On October 16, 2026, Juyuan Research raised its Innovent target to HKD 138.63.
First-half 2026 revenue reached CNY 8.618 billion, up 44.80 percent year over year.
Innovent stock last stood at HKD 89.05 on October 16, 2026 at 4:08 p.m. HKT, up 1.48 percent on Hong Kong's exchange.
Innovent's P/E was 113.34 and its market capitalization was HKD 155.3 billion.

Innovent, KYG4818G1010, Illustration mit AI erstellt.

Juyuan Research raised its target for Innovent stock from HKD 130.25 to HKD 138.63 on October 16, 2026, leaving the target 55.68 percent above the last Hong Kong price. The latest Hong Kong session ended with Innovent at HKD 89.05, up 1.48 percent from HKD 87.75.

Analyst target reaches HKD 138.63

The Juyuan Research note kept a Buy rating and added Innovent's IBI3003 clinical data to its valuation model. According to FUTU, the report cited a 2027 sales target of RMB 20 billion and 2030 revenue guidance of RMB 35 billion to RMB 40 billion. The report also listed risks including weaker first-line IBI363 results and stronger competition in obesity medicines.

First-half revenue rose 44.80 percent

Innovent's operating picture provides the second reference point. In the first half of 2026, revenue reached CNY 8.618 billion, up 44.80 percent from the year-earlier period, while product revenue rose 56.70 percent to CNY 8.201 billion. IFRS net profit reached CNY 1.253 billion, an increase of 50.20 percent year over year, according to FUTU.

Stock remains below its yearly high

Innovent's last price was 20.99 percent below its 52-week high of HKD 112.70 and 28.04 percent above its 52-week low of HKD 69.55. Trading volume reached 9,676,337 shares against an average of 11,655,693, while the market capitalization stood at HKD 155.3 billion.

Valuation and October dates

The stock carried a P/E ratio of 113.34, placing valuation alongside the pipeline's clinical milestones as the main market reference. Innovent announced on September 23, 2026 that data from several oncology and antibody-drug conjugate programs would be presented at the ESMO Annual Meeting from October 23 to October 27, 2026, according to Yahoo Finance. The first listed late-breaking presentation is scheduled for October 23, 2026, at 1:30 p.m. CET.

Comparison with peers

Innovent: plus 1.48 percent, P/E 113.34, market capitalization HKD 155.3 billion

WuXi Biologics (Hong Kong Stock Exchange, HKD): minus 0.90 percent, P/E 34.45, market capitalization HKD 198.4 billion

RemeGen (Hong Kong Stock Exchange, HKD): plus 1.62 percent, P/E 9.66, market capitalization HKD 36.5 billion

Price and investor reference

For investors, the contrast is clear: Innovent combines 44.80 percent first-half revenue growth with a P/E of 113.34, while the Juyuan target implies 55.68 percent upside from the last Hong Kong price. Innovent's last quoted price stood at HKD 89.05 on October 16, 2026 at 4:08 p.m. HKT on the Hong Kong Stock Exchange, up 1.48 percent from HKD 87.75.